- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07520006
Studio di NX-5948 in combinazione con altri agenti negli adulti con neoplasie a cellule B
Uno studio di Fase 1b/2 multicentrico, in aperto, per valutare la sicurezza e l'efficacia di NX-5948 in combinazione con altri agenti in adulti con neoplasie maligne a cellule B
The study will evaluate NX-5948 (bexobrutideg) in combination with venetoclax with or without an anti-CD20 antibody (rituximab or obinutuzumab) in second-line or higher (2L+) relapsed/refractory (R/R) or first-line (1L) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
Panoramica dello studio
Stato
Intervento / Trattamento
Descrizione dettagliata
Bexobrutideg is an investigational drug designed to target a protein called Bruton tyrosine kinase (BTK), which helps cancer cells grow in certain blood cancers like CLL and SLL. Bexobrutideg is a protein degrader, which means it finds and destroys the BTK in the cell. Venetoclax, rituximab, and obinutuzumab are approved medications that are used to treat CLL/SLL.
The study will look at:
- How safe bexobrutideg is for patients with CLL or SLL when taken with these other treatments
- The effects of bexobrutideg in the body when taken with these other treatments
- How well bexobrutideg treats CLL or SLL when taken with these other treatments
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 2
- Fase 1
Contatti e Sedi
Contatto studio
- Nome: Additional Site Contact Information
- Numero di telefono: 415-417-3418
- Email: clinicaltrials@nurixtx.com
Luoghi di studio
-
-
California
-
Irvine, California, Stati Uniti, 92618
- Non ancora reclutamento
- City of Hope Orange County Lennar Foundation Cancer Center
-
-
Colorado
-
Aurora, Colorado, Stati Uniti, 80012
- Reclutamento
- Rocky Mountain Cancer Centers
-
-
Florida
-
Coral Gables, Florida, Stati Uniti, 33146
- Non ancora reclutamento
- University of Miami
-
-
Kansas
-
Kansas City, Kansas, Stati Uniti, 66160
- Non ancora reclutamento
- University of Kansas Cancer Center
-
-
Nevada
-
Las Vegas, Nevada, Stati Uniti, 89169
- Non ancora reclutamento
- Comprehensive Cancer Centers of Nevada
-
-
New Jersey
-
Belleville, New Jersey, Stati Uniti, 07109
- Non ancora reclutamento
- New Jersey Cancer Care
-
-
Oregon
-
Eugene, Oregon, Stati Uniti, 97401
- Reclutamento
- Oncology Associates of Oregon
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Stati Uniti, 15232
- Reclutamento
- UPMC Hillman Cancer Center
-
-
Tennessee
-
Nashville, Tennessee, Stati Uniti, 37203
- Reclutamento
- SCRI Oncology Partners
-
-
Texas
-
Tyler, Texas, Stati Uniti, 75702
- Reclutamento
- Texas Oncology - Northeast
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Key Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
- Adequate organ and bone marrow function
- Measurable disease by computed tomography (CT) per iwCLL
- For R/R CLL/SLL, prior therapy must include treatment with a Bruton tyrosine kinase inhibitor (BTKi)
- For 1L CLL/SLL, confirmed previously untreated CLL/SLL with a clinical indication for systemic treatment that meets iwCLL criteria
- Must sign an informed consent form indicating understanding of the study purpose and procedures and willingness to participate
Key Exclusion Criteria:
- Known or suspected prolymphocytic leukemia or Richter's transformation at any time preceding enrollment
- Investigational agent or anticancer therapy within 5 half-lives or 14 days (whichever is shorter) prior to planned start of study treatment
- Radiotherapy within 2 weeks of the first dose of study drug except for focal palliative radiation
- Use of systemic corticosteroids (>20 mg/day prednisone or equivalent) within the 7 days prior to initiation of study treatment excepting those used as prophylaxis for radiodiagnostic contrast
- Previously treated with a BTK degrader
- Previously treated with a BCL-2 inhibitor (BCL-2i) unless eligible for retreatment
- Known central nervous system (CNS) lymphoma or leukemia
- Myocardial infarction, unstable angina, unstable symptomatic ischemic heart disease, placement of a coronary arterial stent, or any other significant cardiac condition within 6 months of planned start of study treatment
- Thromboembolic events, stroke, or intracranial hemorrhage within 6 months of planned start of study treatment
Note: Other Inclusion/Exclusion criteria may apply as defined in the protocol.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione sequenziale
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: NX-5948 + venetoclax
|
Administered orally once daily as a capsule
Altri nomi:
Administered orally once daily as a tablet per prescribing information |
|
Sperimentale: NX-5948 + venetoclax + rituximab
|
Administered orally once daily as a capsule
Altri nomi:
Administered orally once daily as a tablet per prescribing information Administered as an intravenous (IV) infusion per prescribing information |
|
Sperimentale: NX-5948 + venetoclax + obinutuzumab
|
Administered orally once daily as a capsule
Altri nomi:
Administered orally once daily as a tablet per prescribing information Administered as an IV infusion per prescribing information |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
Numero di partecipanti con eventi avversi emergenti dal trattamento
Lasso di tempo: Fino a circa 7 anni
|
Fino a circa 7 anni
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Objective response rate as determined by investigator
Lasso di tempo: Up to approximately 7 years
|
The percentage of participants with response as determined according to 2018 iwCLL guidelines; response includes complete response (CR)/CR with incomplete marrow recovery (CRi), partial response (PR), PR with lymphocytosis (PR-L), and nodular PR |
Up to approximately 7 years
|
|
Duration of response as determined by investigator
Lasso di tempo: Up to approximately 7 years
|
Time from the date of the first response to the date of documented progressive disease or death due to any cause, whichever is earlier |
Up to approximately 7 years
|
|
Progression-free survival as determined by investigator
Lasso di tempo: Up to approximately 7 years
|
Time from the date of the first dose of study drug to the date of documented progressive disease or death due to any cause, whichever is earlier |
Up to approximately 7 years
|
|
Complete response rate as determined by investigator
Lasso di tempo: Up to approximately 7 years
|
The percentage of participants with CR or CRi as determined according to 2018 iwCLL guidelines; includes CR + CRi for participants with CLL. |
Up to approximately 7 years
|
|
Time to response as determined by investigator
Lasso di tempo: Up to approximately 7 years
|
Time from the start date of study treatment to the date of the first assessment of a response |
Up to approximately 7 years
|
|
Overall survival
Lasso di tempo: Up to approximately 7 years
|
Time from the start date of study treatment to the date of death from any cause |
Up to approximately 7 years
|
|
Pharmacokinetic profile of NX-5948
Lasso di tempo: Up to approximately 1 year
|
NX-5948 concentrations in blood samples |
Up to approximately 1 year
|
|
Pharmacokinetic profile of venetoclax
Lasso di tempo: Up to approximately 1 year
|
Venetoclax concentrations in blood samples |
Up to approximately 1 year
|
|
Change from baseline in Global Health Status/Quality of Life on the European Organization for Research and Treatment of Cancer QoL Questionnaire-Core 30 (EORTC QLQ-C30)
Lasso di tempo: Baseline and up to approximately 27 months
|
Percentage of participants with a clinically meaningful change from baseline using the EORTC QLQ-C30 questionnaire to assess the overall quality of life |
Baseline and up to approximately 27 months
|
|
Change from baseline in European Quality of Life 5-Dimensions, 5-Level Questionnaire (EQ-5D-5L)
Lasso di tempo: Baseline and up to approximately 27 months
|
Percentage of participants with a clinically meaningful change from baseline using the EQ-5D-5L questionnaire to assess health outcomes |
Baseline and up to approximately 27 months
|
Collaboratori e investigatori
Sponsor
Investigatori
- Direttore dello studio: Study Director, Nurix Therapeutics, Inc.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Processi patologici
- Neoplasie
- Malattia cronica
- Attributi della malattia
- Malattie del sistema immunitario
- Neoplasie per tipo istologico
- Malattie ematologiche
- Malattie linfatiche
- Malattie linfoproliferative
- Disturbi immunoproliferativi
- Linfoma non Hodgkin
- Leucemia, cellule B
- Linfoma
- Leucemia, linfoide
- Leucemia
- Condizioni patologiche, segni e sintomi
- Malattie emiche e linfatiche
- Linfoma, cellule B
- Leucemia, linfocitica, cronica, cellule B
- Aminoacidi, peptidi e proteine
- Proteine
- Anticorpi, monoclonali
- Anticorpi
- Immunoglobuline
- Immunoproteine
- Proteine del sangue
- Globuline sieriche
- Globuline
- Anticorpi, monoclonali, derivati da murina
- Rituximab
- Venetoclax
- obinutuzumab
Altri numeri di identificazione dello studio
- NX-5948-203
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .